N,N-bis(cyclohexanol)amine aryl esters: The discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR)

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1715-1731

  Teodori, E ^a   Dei, S ^a   Martelli, C ^a   Scapecchi, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chemosensitizers; K562 cell line; K562 DOX cell line; MDR reversing activity; Multidrug resistance reverters; N; N bis(alkanol)amine aryl esters; N bis(cyclohexanol)amine aryl esters; P gp inhibitors; Pervilleine; Verapamil

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ABC TRANSPORTER; ANTHRACYCLINE; BIRICODAR; CYTOCHROME P450 3A4; DOXORUBICIN; ELACRIDAR; GLYCOPROTEIN P INHIBITOR; LANIQUIDAR; LONAFARNIB; N,N BIS(CYCLOHEXANOL)AMINE ARYL ESTER; OC 144093; ONT 093; PERVILLEINE A; TARIQUIDAR; TIMCODAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VX 853; ZOSUQUIDAR;

ARTICLE; CANCER CELL; CELL STRAIN K 562; CELL STRAIN K 562 DOX; CHRONOTROPISM; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; IC 50; INOTROPISM; MULTIDRUG RESISTANCE; STRUCTURE ACTIVITY RELATION; VASODILATATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL PROLIFERATION; CYCLOHEXYLAMINES; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN;

EID: 77957974158     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928031     Document Type: Article

References (115)

1. Mitscher, L. A.; Pillai, S. P.; Gentry, E. J.; Shankel, D. M. Multiple drug resistance. Med. Res. Rev., 1999, 19, 477-496.
2. Volm, M.; Mattern, J. Resistance mechanisms and their regulation in lung cancer. Crit. Rev. Oncogen., 1996, 7, 227-244.
3. van Veen, H. W.; Konings, W. N. The ABC family of multidrug transporters in microorganisms. Biochim. Biophys. Acta, 1998, 1365, 31-36.
4. Hrycyna, C. A.; Gottesman, M. M. Multidrug ABC transporters from bacteria to man: an emerging hypothesis for the universality of molecular mechanism and functions. Drug Resist. Update, 1998, 1, 81-83.
5. Johnstone, R. W.; Ruefly, A. A.; Tainton, K. M.; Smyth, M. J. A role for P-glycoprotein in regulating cell death. Leuk. Lymphoma, 2000, 38, 1-11.
6. Johnstone, R. W.; Ruefli, A. A.; Smyth, M. J. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci., 2000, 25, 1-6.
7. Kusuhara, H.; Sugiyama, Y. Efflux transport system for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov. Today, 2001, 6, 150-156.
8. Aszalos, A.; Ross, D. D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res., 1998, 18, 2937-2944.
9. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem. Biophys. Acta, 1973, 323, 466-483.
10. Jones P.M.; George A.M. A new structural model for Pglycoprotein. J. Membr. Biol., 1998, 166, 133-147.
11. Robert J. Multidrug resistance reversal agents. Drug Future, 1997, 22, 149-158.
12. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204, 216-237.
13. Dean, M. ABC Transporters, Drug Resistance, and Cancer Stem cells. J. Mammary Gland Biol. Neoplasia, 2009, 14, 3-9.
14. Roninson, I. B.; Abelson, H. T.; Housman, D. E.; Howell, N.; Varshavsky, A. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature, 1984, 309 (5969), 626-628.
15. Riordan, J. R.; Deuchars, K.; Kartner, N.; Alon, N.; Trent, J.; Ling, V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature, 1985, 316 (6031), 817-819.
16. Gros, P.; Croop, J.; Housman, D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell, 1986, 47(3), 371-380.
17. Loo T. W.; Clarke D. M. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem. Cell Biol., 1999, 77, 11-23.
18. Jones P. M.; George A. M.; Symmetry and structure in P-glycoprotein and ABC transporters: what goes around comes around. Eur. J. Biochem., 2000, 267, 5298-5305.
19. Hyde, S. C.; Emsley, P.; Hartshorn, M. J.; Mimmack, M. M.; Gileadi, U.; Pearce, S. R.; Gallagher, M. P.; Gill, D. R.; Hubbard, R. E.; Higgins, C. F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346 (6282), 362-365.
20. Rosenberg, M. F.; Velarde, G.; Ford, R. C.; Martin, C.; Berridge, G.; Kerr, I. D.; Callaghan, R.; Schmidlin, A.; Wooding, C.; Linton, K. J.; Higgins, C. F. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J., 2001, 20 (20), 5615-5625.
21. Senior, A. E.; Gadsby D.C. ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. Cancer Biol., 1997, 8, 143-150.
22. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene 1650 in a multidrug-resistant human lung cancer cell line. Science, 1992, 258, 1650-1654.
23. Daoud, R.; Julien, M.; Gros, P.; Georges, E. Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17. J. Biol. Chem., 2001, 276, 12324-12330.
24. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Nat. Canc. Inst., 2000, 92, 1295-1302.
25. Rosenberg, M. F.; Kamis, A. B.; Callaghan, R.; Higgins, C. F.; Ford, R. C. Three dimensional structures of the mammalian multidrug-resistant P-glycoprotein demonstrate major conformational changes in the transmembrane domain upon nucleotide binding. J. Biol. Chem., 2003, 278, 8294-8299.
26. Troost, J.; Lindenmaier, H.; Haefeli, W. E.; Weiss, J. Modulation of cellular cholesterol alters p-glycoprotein activity in multidrugresistant cells. Mol. Pharmacol., 2004, 66, 1332-1339.
27. Rosenberg, M. F.; Callaghan, R.; Modok, S.; Higgins, C. F.; Ford, R. C. Three-dimensional structure of P-glycoprotein. J. Biol. Chem., 2005, 280, 2857-2862.
28. Dawson, R. J.; Locher, K. P. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett., 2007, 581, 935-938.
29. Dawson, R. J.; Locher, K. P. Structure of a bacterial multidrug ABC transporter. Nature, 2006, 443, 180-185.
30. Higgins, C. F. Multiple molecular mechanisms for multidrug resistance transporters. Nature, 2007, 446, 749-757.
31. Zolnerciks, J. K.; Wooding, C.; Linton, K. J. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J., 2007, 21, 3937-3948.
32. O'Mara, M. L.; Tieleman, D. P. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and Ma1K. FEBS Lett., 2007, 581, 4217-4222.
33. Globisch, C.; Pajeva, I. K.; Wiese, M. Identification of putative binding sites of P-glycoprotein based on its homology model. Chem. Med. Chem., 2008, 3, 280-295.
34. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
35. Yu, E. W.; McDermott, G.; Zgurskaya, H. I.; Nikaido, H.; Koshland, D. E. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science, 2003, 300, 976-980.
36. Murray, D. S.; Schumacher, M. A.; Brennan, R. G. Crystal structure of QacR-diamidine complexes reveal additional multidrugbinding modes and a novel mechanism of drug charge neutralization. J. Biol. Chem., 2004, 279, 14365-14371.
37. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science, 2009, 323, 1718-1722.
38. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J., 2006, 396, 537-545.
39. Schumacher, M. A.; Miller, M. C.; Brennan, R. G. Structural mechanism of the simultaneous binding of two drugs to a multidrug binding protein. EMBO J., 2004, 23, 2923-2930.
40. Dei, S.; Gualtieri, F.; Scapecchi, S.; Teodori, E.; Garnier-Suillerot, A. Mediators of classical multidrug resistance (MDR) and the medicinal chemistry of reversing drugs in Recent Res. Develop. Med. Chem., TRN/MC: Trivandrum, India, 2001, pp. 17-64.
41. Bolhuis, H.; van Veen, E. W.; Poolman, B.; Driessen, A. J. M.; Konings, W. N. Mechanisms of multidrug transporters. FEMS Microbiol. Rev., 1997, 21, 55-84.
42. Sauna, Z. E.; Kim, I.-W.; Nandigama, K.; Kopp, S.; Chiba, P.; Ambudkar, S. V. Catalytic cycle of ATP hydrolysis by G-glycoprotein: evidence for formation of E-S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analog of ATP. Biochemistry, 2007, 46, 13787-13799.
43. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug. Targets, 2006, 7, 861-879.
44. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets, 2006, 7, 893-909.
45. Avendano, C.; Menendez, J. C. Recent advances in multidrug resistance modulators. Med. Chem. Rev.-Online, 2004, 1, 419-444.
46. Robert, J.; Jarry, C. Multidrug resistance reversal agents. J. Med. Chem., 2003, 46, 4805-4817.
47. Fusi, F.; Saponara, S.; Valoti, M.; Dragoni, S.; D'Elia, P.; Sgaragli, T.; Alderighi, D.; Kawase, M.; Shah, A.; Motohashi, N.; Sgaragli, G. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets, 2006, 8, 949-959.
48. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol., 2000, 12, 450-458.
49. Robey, R. W.; Lazarowski, A.; Bates, S. E. P-glycoprotein a clinical target in drug-refractory epilepsy? Mol. Pharmacol., 2008, 73, 1343-1346.
50. Owen, A.; Chandler, B.; Back, D. J. The implications of P-glycoprotein in HIV: friend or foe? Fund. Clin. Pharmacol., 2005, 19, 283-296.
51. Teodori, E.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Martelli, C.; Romanelli, M. N.; Scapecchi, S.; Paiwan, S.; Salerno, M. Exploratory chemistry toward the identification of a new class of MDR reverters inspired by pervilleine and verapamil models. J. Med. Chem., 2005, 48, 7426-7436.
52. Martelli, C.; Coronnello, M.; Dei, S.; Manetti, D.; Orlandi, F.; Scapecchi, S.; Romanelli, M.N.; Salerno, M.; Mini, E.; Teodori, E. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J. Med. Chem., 2010, 53(4), 1755-1762.
53. Teodori, E.; Dei, S.; Scapecchi, S.; Gualtieri, F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Il Farmaco, 2002, 57, 385-415.
54. Sorbera, L. A.; Castaner, J.; Silvestre, J. S.; Bayés, M. Zosuquidar trihydrochloride. Drug Future, 2003, 28, 125-136.
55. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. Multidrug resistance (MDR) modulators: Verapamil offsprings and heterocyclic derivatives. In: Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment, Colabufo, N.; Ed.; Research Signpost, Kerala, India, 2008, pp 141-169.
56. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil. Cancer Res., 1981, 41, 1967-1972.
57. Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest, 1986, 77, 1405-1408.
58. Tsuruo, T.; Iida, H.; Kitatani, Y.; Yokota, K.; Tsukagoshi, S.; Sakurai, Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res., 1984, 44, 4303-4307.
59. Tsuruo, T.; Iida, H.; Nojiri, M.; Tsukagoshi, S.; Sakurai, Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res., 1983, 43, 2905-2910.
60. Atalay, C. Multi-drug resistance and cancer. Expert Opin. Ther. Patents, 2007, 17, 511-20.
61. Lum, B. L.; Gosland, M. P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North. Am., 1995, 9, 319-336.
62. Modok, S.; Mellor, H. R.; Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol., 2006, 6, 350-354.
63. McDevitt, C. A.; Callaghan, R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther., 2007, 113, 429-441.
64. Slate, D. L.; Bruno, N. A.; Casey, S. M.; Zutshi, N.; Garvin, L. J.; Wu, H.; Pfister, J. R. RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res., 1995, 15, 811-814.
65. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.; Hunjan, S.; Pretswell, I.; Dangerfield, W.; Ryder, H.; Charlton, P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett., 1999, 9, 595-600.
66. Newman, M. J.; Rodarte, J. C.; Benbatoul, K. D.; Romano, S. J.; Zhang, C.; Krane, S.; Moran, E. J.; Uyeda, R. T.; Dixon, R.; Guns, E. S.; Mayer, L. D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res., 2000, 60, 2964-2972.
67. Hodgkinson, R.; Sharples, D. Reversing antibiotic resistance. Expert Opin. Invest. Drugs, 2002, 11, 1023-1032.
68. Klopman, G.; Shi, L. M.; Ramu, A. Quantitative structure-activity relationship of multidrug reversal agents. Mol. Pharmacol., 1997, 52, 323-334.
69. Zamora, M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol., 1988, 33, 454-462.
70. Nogai, I.; Kohno, K.; Kikuchi, J.; Kuwano, M.; Akiyama, S.; Kiue, A.; Suzuki, K.; Yoshida, Y.; Cornwell, M. M.; Pastan, I.; Gottesman, M. M. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem. Pharmacol., 1989, 38, 519-527.
71. Pearce, H. L.; Safa, A. R.; Bach, N. J.; Winter, M. A.; Cirtain, M. C.; Beck, W. T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA, 1989, 86, 5128-5132.
72. Ford, J. M.; Prozialeck, W. C.; Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol., 1989, 35, 105-115.
73. Pearce, H. L.; Winter, M. A.; Beck, T. V. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul., 1990, 30, 357-372.
74. Pommerenke, E. W.; Osswald, H.; Hahn, E. W.; Volm, M. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Lett., 1990, 55, 17-23.
75. Klopman, G.; Srivastava, S.; Kolossvary, I.; Epand, R. F.; Ahmed, N.; Epand, R. M. Structure-activity study and design of multidrug resistance reversal compounds by a computer automated structure evaluation methodology. Cancer Res., 1992, 52, 4121-4129.
76. Ramu, A.; Ramu, N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemoth. Pharmacol., 1992, 30, 165-173.
77. Ramu, A.; Ramu, N. Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds. Cancer Chemother. Pharmacol., 1994, 34, 423-430.
78. Wiese, M.; Pajeva, K. Structure activity relationships of multidrug resistance reversers. Curr. Med. Chem., 2001, 8, 685-713.
79. Stouch, T. R.; Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev., 2002, 54, 315-328.
80. Pajeva, I.; Wiese, M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J. Med. Chem., 1998, 41, 1815-1826.
81. Chiba, P.; Holzer, W.; Landau, M.; Bechmann, G.; Lorenz, K.; Plagens, B.; Hitzler, M.; Richter, E.; Ecker, G. Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity. J. Med. Chem., 1998, 41, 4001-4011.
82. Dearden, J. C.; Al-Noobi, A.; Scott, A. C.; Thomson, S. A. QSAR studies on P-glycoprotein-regulated multidrug resistance and on its reversal by phenothiazines. SAR QSAR Environ. Res., 2003, 14, 447-454.
83. Tsakovska, I. M. QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells. Bioorg. Med. Chem., 2003, 11, 2889-2899.
84. Pleban, K.; Hoffer, C.; Kopp, S.; Peer, M.; Chiba, P.; Ecker, G. F. Intramolecular distribution of hydrophobicity influences pharmacological activity of propafenone-type MDR modulators. Arch. Pharm., 2004, 337, 328-334.
85. Li, Y.; Wang, Y.-H.; Yang, L.; Zhang, S.-W.; Liu, C.-H. and Yang, S.-L. Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis. J. Mol. Struct., 2005, 733, 111-118.
86. Chiba, P.; Ecker, G.; Schmid, D.; Drach, J.; Tell, B.; Goldemberg, S.; Gekeler, V. Structural requirements for activity of propafenonetype modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol., 1996, 49, 1122-1130.
87. Schmid, D.; Ecker, G.; Kopp, S.; Hitzler, M.; Chiba, P. Structure activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem. Pharmacol., 1999, 58, 1447-1456.
88. Pereira, E.; Teodori, E.; Dei, S.; Gualtieri, F.; Garnier-Suillerot, A. Reversal of multidrug resistance by verapamil analogues. Biochem. Pharmacol., 1995, 50, 451-457.
89. Teodori, E.; Dei, S.; Quidu, P.; Budriesi, R.; Chiarini, A.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Scapecchi, S. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J. Med. Chem., 1999, 42, 1687-1697.
90. Pajeva, I. K.; Globisch, C.; Wiese, M. Structure function relationships of multidrug resistance P-glycoprotein. J. Med. Chem., 2004, 47, 2523-2533.
91. Pajeva, I. K.; Wiese, M. Pharmacophore model of drugs involved in p-glycoprotein multidrug resistance: Explanation of structural variety (Hypothesis). J. Med. Chem., 2002, 45, 5671-5686.
92. Seelig, A., Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci., 2000, 12, 31-40.
93. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharmacol. Ther., 2003, 28, 203-228.
94. Dei, S.; Romanelli, M. N.; Scapecchi, S.; Teodori, E.; Chiarini, A.; Gualtieri, F. Verapamil analogues with restricted molecular flexibility. J. Med. Chem., 1991, 34, 2219-2225.
95. Dei, S.; Romanelli, M. N.; Scapecchi, S.; Teodori, E.; Chiarini, A.; Gualtieri, F.; Voigt, W.; Lemoine, H. Verapamil analogs with restricted molecular flexibility: synthesis and pharmacological evaluation of the four isomers of alpha-[1-[3-[N-[1-[2-(3,4-dimethoxyphenyl) ethyl]]-N-methylamino]cyclohexyl]]-alphaisopropyl-3,4-dimethoxybenzeneacetonitrile. J. Med. Chem., 1993, 36, 439-445.
96. Romanelli, M. N.; Dei, S.; Scapecchi, S.; Teodori, E.; Gualtieri, F.; Budriesi, R.; Mannhold, R. Semi-rigid analogues of the calcium antagonist verapamil: a molecular modelling study. J. Comp.-Aid. Mol. Des., 1994, 8, 123-134.
97. Teodori, E.; Dei, S.; Romanelli, M. N.; Scapecchi, S.; Gualtieri, F.; Budriesi, R.; Chiarini, A.; Lemoine, H.; Mannhold, R. Synthesis and pharmacological evaluation of verapamil analogs with restricted molecular flexibility. Eur. J. Med. Chem., 1994, 29, 139-148.
98. Pawagi, A. B.; Wang, J.; Silverman, M.; Reithmeier, R. A. F.; Deber, C. M. Transmembrane aromatic amino acid distribution in p-glycoprotein: A functional role in broad substrate specificity. J. Mol. Biol., 1994, 235, 554-564.
99. Dei, S.; Teodori, E.; Garnier-Suillerot, A.; Gualtieri, F.; Scapecchi, S.; Budriesi, R.; Chiarini, A. Structure-activity relationships and optimisation of the selective MDR modulator 2-(3,4-dimethoxyphenyl)-5-(9-fluorenylamino)-2-(methylethyl) pentanenitrile (SC11) and its N-methyl derivative (SC17). Bioorg. Med Chem., 2001, 9, 2673-2682.
100. Mankhethorn, S.; Teodori, E.; Scapecchi, S.; Garnier-Suillerot, A. Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue. Biochem. Pharmacol., 1996, 52, 213-217.
101. Teodori, E.; Ettori, D.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Scapecchi, S. Synthesis and binding properties of photoactivable biotin-conjugated verapamil derivatives for the study of P-170 glycoprotein. Bioorg. Med. Chem., 1999, 7, 1873-1880.
102. Dei, S.; Budriesi, R.; Sudwan, P.; Ferraroni, M.; Chiarini, A.; Garnier-Suillerot, A.; Manetti, D.; Martelli, C.; Scapecchi, S.; Teodori, E. Diphenylcyclohexylamine derivatives as new potent multidrug resistance (MDR) modulators. Bioorg. Med. Chem., 2005, 13, 985-988.
103. Teodori, E.; Dei, S.; Garnier-Suillerot, A.; Quidu, P.; Scapecchi, S.; Budriesi, R. Structure-activity relationship studies on the potent multidrug resistance (MDR) modulator 2-(3,4-dimethoxyphenyl)-2-(methylethyl)-5-[(anthr-9-ylmethylamino]pentanenitrile (MM36). Med. Chem. Res., 2001, 10, 563-576.
104. Biscardi, M.; Teodori, E.; Caporale, R.; Budriesi, R.; Balestri, F.; Scappini, B.; Gavazzi, S.; Grossi, A. Multidrug reversing activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk. Res., 2006, 30, 1-8.
105. Chavez, D.; Cui, B.; Chai, H. B.; Garcia, R.; Mejia, M.; Farnsworth, N. R.; Cordel, G. A.; Pezzuto, J. M.; Kinghorn, A. D. Reversal od multidrug resistance by tropane alkaloids from the stems of erythroxylum rotundifolium. J. Nat. Prod., 2002, 65, 606-610.
106. Mi, Q.; Cui, B.; Silva, G. L.; Lantvit, D.; Lim, E.; Chai, H.; Hollingshead, M. G.; Mayo, J. G.; Kinghorn, D.; Pezzuto, J. M. Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug resistance in the hollow fiber assay. Cancer Lett., 2002, 184, 13-20.
107. Mi, Q.; Cui, B.; Lantvit, D.; Reyes-Lim, E.; Chai, H.; Pezzuto, J. M.; Kinghorn, D.; Swanson, S. M. Pervilleine F, a new topane alkaloid aromatic ester that reverses multidrug resistance. Anticancer Res., 2003, 23, 3607-3616.
108. Sauna, Z. E.; Andrus, M. B.; Turner, T. M.; Ambudkar, S. V. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy. Biochemistry-US, 2004, 43, 2262-2271.
109. Andrus, M. B.; Turner, T. M.; Updegraf, E. P.; Sauna, Z. E.; Ambudkar, S. V. Synthesis and analysis of polyethylene glycol linked P-glycoprotein-specific homodimers based on (-) stipiamide. Tetrahedron Lett., 2001, 42, 3819-3822.
110. Cianchetta, G.; Singleton, R. W.; Zhang, M.; Wildgoose, M.; Glesing, D.; Fravolini, A.; Cruciani, G.; Vaz, R. J. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRID-based 3D-QSAR. J. Med. Chem., 2005, 48, 2927-2935.
111. Teodori, E.; Martelli, C.; Salerno, M.; Darghal, N.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Scapecchi, S.; Romanelli, M. N. Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors. J. Med. Chem., 2007, 50, 599-602.
112. Martelli C.; Alderighi D.; Coronnello M.; Dei S.; Frosini M.; Le Bozec B.; Manetti D.; Neri A.; Romanelli M. N.; Salerno M.; Scapecchi S.; Mini E.; Sgaragli G.; Teodori E. N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors. J. Med. Chem., 2009, 52, 807-817.
113. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical properties profiles of development and marketed oral drugs. J. Med. Chem., 2003, 46, 1250-1256.
114. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-2623.
115. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. O. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Expt. Ther., 2001, 299, 620-628.